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ABSTRACT 
New antibacterials need new approaches to overcome the problem of rapid 
antibiotic resistance. Here we review the development of potential new 
antibacterial drugs that do not kill bacteria or inhibit their growth, but combat 
disease instead by targeting bacterial virulence.  
 
 
INTRODUCTION 
In the ongoing battle between people and pathogens, the pendulum seems to be 
swinging in favour of the bugs. The rapid increase in resistance to antibiotics 
combined with the slowing to a trickle of new antibiotics progressing through the 
pipeline over the past decades has led to this point. The situation has been described 
by the Infectious Diseases Society of America as a looming “public health crisis” [1]. 
 
There are any number of reasons why pathogenic bacteria acquire antibiotic resistance, 
and why resistance is growing at such an alarming rate. The question is, given where 
we are now, how can we ensure that the pendulum swings back in our favour? One 
school of thought is that we need to change the way we discover new antibiotics. 
Historically, antibiotics have been identified by their ability to kill or inhibit growth 
of bacteria. A prime example is penicillin, originally identified by Fleming’s 
serendipitous discovery that a penicillium mould inhibited bacterial growth on an agar 
plate. Ever since, screening approaches have been engineered to find chemicals that 
do the same thing, and molecular approaches have focused on identifying essential 
genes to target for drug intervention. The problem with therapeutic approaches that A
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target viability is that they induce a high selection pressure. A bacterium exhibiting 
resistance to the antibiotic will have an enormous selective advantage over its 
competitors in a bacterial population, so that resistance will develop rapidly in the 
presence of that antibiotic. 
 
An alternative to killing bacteria or stopping their growth, is to search for drugs that 
disarm bacteria. This idea focuses on developing drugs that inhibit bacterial virulence 
[2-4] rather than bacterial viability (Figure 1). Targeting virulence offers several 
potential advantages including: 
(i) an increased repertoire of pharmacological targets 
(ii) generating antimicrobials with new mechanisms of action 
(iii)reducing resistance development due to decreased selective pressure [3] 
(iv) and potentially preserving gut microbiota.  
 
On the other hand, development of antivirulence therapies presents its own unique 
challenges. We can no longer use established screening systems that identify 
compounds that kill or inhibit growth of bacteria. And minimal inhibitory 
concentration measures are obsolete in this scenario. Specific in vitro and in vivo 
assays will need to be developed to screen for compounds that inhibit specific 
virulence processes. And, given that virulence mechanisms vary from one bacteria to 
another, antivirulence drugs are likely to have a narrow spectrum of activity. Their 
success in the clinic may well depend on development of real time diagnostics that 
identify the causative organism and enable therapy personalised to the infectious 
agent. 
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In this review we highlight several virulence pathways currently being targeted for the 
development of antivirulence drugs, including adhesion, secretion and toxin 
production (Figure 2, summarised in Table 1). We also highlight two master virulence 
targets that coordinate deployment of entire arsenals of virulence factors either by 
communicating information (quorum sensing) (Figure 2, Table 1) or by assembling an 
armoury of bacterial weapons (oxidative folding) (Figure 3). Drugs that block these 
master systems may have a broader spectrum of activity.  
 
TARGETING OCCUPATION 
A crucial first step in colonization by bacteria is adhesion to host cells; blocking this 
process may prevent establishment and maintenance of infection [4]. Adhesion is 
mediated by surface proteins (adhesins, autotransporters etc) and multi-protein 
scaffolds (eg pili) protruding from bacteria that interact specifically with 
carbohydrates on the host cell surface.  
 
In Gram-positive organisms, adhesion depends on sortases, a family of cysteine 
transpeptidases that covalently anchor adhesin proteins to the bacterial cell wall [5, 6]. 
Sortases have been targeted in several antibacterial drug discovery programs and 
screening against S. aureus and Bacillus anthracis have identified hits which could 
potentially be developed into potent sortase inhibitor drugs [7-11].  
 
By contrast, cell adhesion and invasion in Gram-negative organisms generally relies 
on the production of pili [4]. Two strategies have been developed to block pilus-
mediated adhesion. One is the identification of pilicides, molecules that prevent pili 
biogenesis by interfering with the underlying usher-chaperone pathway [12]. Pilicides A
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have been shown to reduce production of several components of this pathway in 
uropathogenic E. coli including type I and P pili fimbrial proteins [13]; Dr family 
adhesins [14]; and curli [15], with some also preventing biofilm formation [12, 15]. 
Significantly, the usher-chaperone pili assembly machinery is present in many species 
including Escherichia, Salmonella, Klebsiella, Yersinia and Pseudomonas [16] 
suggesting that pilicides may have a broad spectrum of activity [17].  
 
A second strategy to inhibit pili-based adhesion relies on physically blocking the 
interaction between the adhesin and the host cell. The carbohydrate binding site is 
localised at the very tip of the pili. Carbohydrate derivatives and molecules 
mimicking mammalian glycans dramatically reduce the adhesive properties of 
bacterial pili [18-20]. Importantly, one such inhibitor prevented acute infection in vivo 
and also treated chronic cystitis caused by a multi-resistant E. coli in an animal model 
[18]. 
 
TARGETING WEAPONS DELIVERY 
Bacteria have evolved complex machineries to deliver proteins and toxins into a host 
cell across membranes and cell walls, and these machineries play a central role in 
pathogenesis. The system attracting most attention is the Type III secretion system 
(TTSS). This syringe-like multiprotein apparatus injects bacterial effector proteins 
and toxins directly into the host cell cytosol, and thereby hijacks a wide range of 
cellular processes [21]. Many components of the TTSS are specific to prokaryotes and 
several studies have explored TTSS inhibitors as potential therapeutics (recently 
reviewed in [22]). Importantly, the TTSS machinery is present in many pathogens 
including Escherichia, Shigella, Salmonella, Pseudomonas, Chlamydia and Yersinia A
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spp., so that targeting common elements could result in broad-spectrum TTSS 
inhibitors [23]. 
 
Indeed, high-throughput screening identified thiazolidinone derivatives that block 
TTSS from Gram-negative pathogens including S. Typhimurium and Yersinia 
enterocolitica, reduced the virulence of Pseudomonas syringae and inhibited other 
secretion systems such as the Type II in Pseudomonas and the Type IV in Francisella 
[24]. Similarly, small molecule screening identified a series of salicylidene 
acylhydrazides capable of inhibiting the TTSS of intracellular (Chlamydia 
trachomatis) and extracellular pathogens (Yersinia ssp.) [25-27]. Some of these 
compounds showed protective activity against the sexually transmitted pathogen C. 
trachomatis in mouse infection models [28]. 
 
TARGETING TOXINS 
Toxins are the primary virulence factors of many bacterial pathogens. Examples 
include botulinum and tetanus neurotoxins, cholera, anthrax, diphtheria and Shiga 
toxins. All are proteins delivered into the host to cause mass cell destruction and 
tissue damage [29]. Their extreme toxicity and critical role in pathogenesis makes 
inhibition of toxin production an obvious approach for development of antivirulence 
antimicrobials. This can be achieved by targeting toxin transcription and expression: 
virstatin inhibits the transcription factor ToxT that regulates expression of cholera 
toxin and cholera co-regulated pilus, and blocks intestinal colonization by this 
pathogen in murine models [30]. Similarly, a small molecule inhibitor of toxin TcdA 
and TcdB expression by Clostridium difficile, has shown efficacy in a hamster model 
of gastrointestinal infection [31]. A
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Antibodies have been developed to neutralise toxins and are already used to treat 
bacterial diseases such as tetanus, diphtheria and botulism [32]. For example, 
botulism toxin neutralizing antibodies from horse sera are used to treat adult botulism 
and a human-derived botulism antitoxin has been used to treat infants [33]. These 
outcomes provide clinical evidence validating the use of antitoxin drugs after 
infection. 
 
Other antibody therapies are at different stages of development [34]. For example, 
antibodies against Shiga toxin were shown to protect against Shiga toxin-producing E. 
coli (STEC) in a piglet model of acute gastroenteritis [35]. Similarly, efficacy was 
demonstrated in mouse and hamster infection models by combining human antibodies 
against C. difficile toxins A and B [36]. The potential use of B. anthracis as a 
bioweapon has made this and other high threat pathogens the focus of intense efforts 
to develop antibodies and vaccines [37]. Antibodies that inhibit anthrax toxins 
(ABthrax, Valortim among others) have shown promising protection in a range of 
animal models and are now in clinical development [38-41]. 
 
TARGETING COMMUNICATION SYSTEMS 
Bacterial cell-to-cell communication is essential for microbes to adapt to changing 
environments and this communication is regulated by Quorum Sensing (QS) networks. 
Gram-positive and Gram-negative bacteria both use complex regulatory QS circuits to 
sense their population densities and regulate the expression of virulence factors, 
allowing successful establishment of infection [42]. The canonical QS pathways 
consist of secreted signal molecules known as autoinducers (AI, e.g. acyl-homoserine A
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lactones (AHLs) in many Gram-negative bacteria, autoinducing peptides (AIPs) in 
Gram-positive bacteria). Upon reaching a threshold concentration, AI molecules 
interact with cognate sensor receptors (e.g. LuxR and LuxS receptors) to induce the 
expression of virulence genes. 
 
Given the central role of QS systems in bacterial pathogenesis, many efforts have 
focused on interfering with these pathways (recently reviewed in [43-48]). Quorum 
quenching is a term that has been used to describe “any approach that interferes with 
microbial QS signalling” [49]. QS networks have been quenched or modulated at 
three points (reviewed in [49]) by: (1) inhibiting signal generation (e.g. by blocking 
synthesis of AHL in vitro using AHL analogues [50, 51]), (2) degrading the signal 
molecule (AHLs can be destroyed chemically by increasing the pH [2] or by use of 
“quorum quenching” enzymes [47], or inactivated with antibodies [52]), and (3) 
blocking the interaction of the QS signal molecule with the receptor. The last is the 
most popular approach. Screening of natural and synthetic compounds has produced 
potent antagonists of sensing receptors for many bacteria (e.g. enterobacteria, 
Pseudomonas, Staphylococci) with some antagonists being protective in animal 
models of infection (reviewed in [53]). Furthermore, inhibitors capable of blocking 
QS networks in several Gram-negative pathogens, open the possibility of QS 
inhibitors with broad spectrum activity [54]. 
 
The increasing number of patent applications for QS inhibitors clearly reflects the 
interest in this approach [55]. Notably, targeting QS has yielded potent molecules that 
prevent biofilm formation, a major hurdle in treating many bacterial infections [47]. 
Although a lower risk of resistance development was predicted for QS-regulating A
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molecules, recent data indicate that bacteria can develop resistance to these 
compounds [56]. For example, the QS inhibitor C-30 [57] had no effect on the growth 
of Pseudomonas aeruginosa in rich media, but in minimal media it did affect bacterial 
growth and selected for resistance [58].  
 
TARGETING WEAPONS ASSEMBLY 
Virulence factors produced by bacteria are generally proteins, and these virulence 
proteins need to be assembled correctly to function. An important feature of many 
virulence factor proteins produced by Gram-negative bacteria is the requirement for 
structural bracing in the form of disulfide bonds. Disulfide formation between pairs of 
cysteine residues increases the chemical and physical stability of proteins. Conversely, 
failure to form native disulfide bonds results in degradation and loss of activity.  
 
Oxidative protein folding, the process of introducing disulfide bonds into folding 
proteins, is a rate-limiting step in the assembly of many virulence factors and requires 
the activity of specific enzymes [59]. The classic bacterial disulfide bond (DSB) 
machinery, first characterised in E. coli K-12[60], comprises a soluble periplasmic 
enzyme DsbA and an integral membrane protein DsbB (Figure 3). DsbB and its 
quinone cofactor together generate disulfides de novo, and transfer them to DsbA[61] 
which introduces disulfides directly into folding proteins[62].  
 
 
Whilst some variation exists in the DSB enzymes in different bacteria (reviewed in 
[63]), there is now overwhelming evidence that the DSB oxidative protein folding 
machinery is a master regulator of bacterial virulence. Recent compelling evidence A
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comes from a study using an animal model of melioidosis in which mice infected with 
the causative agent of melioidosis, Burkholderia pseudomallei, all died within 42 days 
whereas mice infected with B. pseudomallei lacking the gene for DsbA all 
survived[64]. Similarly, animal infection models have demonstrated that deletion of 
dsbA or dsbB in uropathogenic E. coli (UPEC) severely attenuated its ability to 
colonize the bladder[65], and that dsbA mutants in Salmonella enterica serovar 
Typhimirium were avirulent[66]. 
 
Indeed, many bacteria lacking a functional DsbA have been shown to have reduced 
virulence, increased sensitivity to antibiotics and diminished capacity to cause 
infection. These include uropathogenic E. coli (UPEC), enteropathogenic E. coli 
(EPEC), Bordetella pertussis (whooping cough), Vibrio cholerae (cholera), P. 
aeruginosa (opportunistic human pathogen), Haemophilus influenzae (opportunistic 
human pathogen), S. flexneri (diarrhoea) and Neisseria meningitidis (bacterial 
meningitis) amongst others [67-74].  
 
The loss of virulence can be attributed to the misfolding of a (normally) disulfide-
containing protein substrate of DsbA. For example, E. coli dsbA mutants are non-
motile. The loss of motility is a consequence of the misfolding of protein FlgI, a 
component of the periplasmic ring of the flagellar motor, and a DsbA substrate[75]. 
DsbA is also required for the correct folding of virulence proteins involved in 
bacterial adhesion, secretion and toxicity. Similarly, mutational inactivation of dsbB 
also affects bacterial virulence[76].  
 
These observations point to a major regulatory role in virulence and identify the DSB A
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enzymes as key targets for the development of anti-virulence agents. The DSB 
machinery offers a number of advantages as antibacterial drug targets including:  
(i) DSB inhibition affects multiple bacterial virulence pathways; 
(ii) DSB enzymes are localised to the outer compartment of bacteria making drug 
delivery more amenable than cytoplasmic targets;  
(iii)DsbAs are more highly conserved than the virulence factors they assemble, so 
that inhibitors are likely to be effective against multiple pathogens; and 
(iv) Structures of DSB enzymes are in the public domain, so that structure-based 
approaches for drug discovery are supported. 
 
However, whereas DSB systems are conserved and required for pathogenicity in 
Gram-negative bacteria, the link between DSB systems and virulence in Gram-
positive organisms is not confirmed. Moreover, to our knowledge, there are no reports 
of small molecule inhibitors of DSB enzymes that are effective in vivo. Indeed, they 
represent challenging targets for drug design. Structures of DsbA and DsbB reveal 
that their interaction surfaces lack deep binding cavities, which is often an 
impediment to inhibitor design. Nevertheless, there are an increasing number of 
examples of small molecules designed to block protein-protein interactions against 
other targets [77]. Furthermore, screening of small molecule “fragments” identified 
compounds that interacted with DsbB and led to a series of compounds capable of 
inhibiting DsbB in vitro [78]. If we can develop inhibitors of DSB-mediated oxidative 
protein folding, these would have enormous value as antivirulence agents by 
potentially blocking the assembly of multiple bacterial virulence factors. 
 
SUMMARY A
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In the search for future antibacterials to overcome antibiotic resistance, antivirulence 
agents promise more than a glimmer of hope. Several strategies have been put 
forward, and target validation and preliminary screening have been performed to 
identify important virulence pathways and master virulence machineries. However, 
aside from antibodies that inactivate specific bacterial toxins, none of these 
compounds with new mechanisms of actions have yet reached the clinic. So it 
remains to be seen whether all or some of these antivirulence approaches will live up 
to expectations. We eagerly await studies showing how new generation antivirulence 
antibacterials perform, whether they will reduce resistance development, whether they 
will need to be combined with traditional antibiotics, or whether they can resurrect 
antibiotics made obsolete by bacterial resistance mechanisms. 
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Table 1. Selected examples of virulence factor inhibitors 
 
 
                         Mode of action 
Selection of studied 
pathogens 
Ref. 
 
Adhesion Inhibitors 
Aaptamines Natural product sortase A 
inhibitors  
S. aureus [8] 
Pyridazinone and 
pyrazolethione 
derivatives 
Synthetic sortase A inhibitors S. aureus, B. anthracis [11] 
Pilicides Regulate pilus biogenesis by 
blocking the chaperone/usher 
assembly pathway 
E. coli [12] 
 
Toxin Inhibitors 
Virstatin Inhibits ToxT transcription 
factor blocking expression of 
cholera toxin  
V. cholerae [30] 
ABthrax, 
Valortim 
Antibodies; inhibit anthrax 
toxins 
B. anthracis [38-
41] 
 
TTSS Inhibitors 
Thiazolidinone 
derivatives 
Prevent translocation of 
effector molecules  
Yersinia, Salmonella, 
Francisella, Pseudomonas 
[24] 
Salicylidene 
acylhydrazides 
Prevent translocation of 
effector molecules 
Escherichia, 
Yersinia, Chlamydia, 
Pseudomonas, Salmonella, 
Shigella 
[28] 
 
QS Inhibitors 
Furanone 
derivatives 
Inhibitors mimic AHLs; bind 
LuxR receptor and inhibit 
QS-regulated gene expression 
E. coli, P.aeruginosa, Proteus 
mirabilis, Staphylococci 
[53] 
Lactonase and 
acylase  
“Quorum quenching” 
enzymes degrade AHL, to 
block the quorum sensing 
response 
Bacillus ssp, Erwinia 
carotovora, P. aeruginosa, 
Pectobacterium carotovorum 
[47, 
53] 
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FIGURE LEGENDS 
Figure 1. Antibiotics and anti-virulence agents. Antibiotics (left) kill bacteria or 
prevent their growth. Antivirulence agents (right) render bacteria harmless by 
blocking the activity of virulence factors. Virulence factors can include toxins 
(denoted by poison sign), secretion systems (syringe), adhesion factors (grappling 
hook), or quorum sensing (walkie-talkie), amongst others. 
 
Figure 2. Examples of bacterial virulence pathways that have been targeted for 
antimicrobial development. Bacterial adhesion to the host cell; 1. Inhibitors of pili 
biosynthetic machineries (e.g. chaperone/usher pathway); 2. Inhibitors of the 
carbohydrate-binding sites in the adhesin molecules. Bacterial secretion systems; 3. 
Inhibitors of the Type Three Secretion system (TTSS) to block injection of effector 
proteins to the host cell. Toxin production; 4. Toxin neutralisation to inhibit damage 
to the host. Acyl-homoserine lactone (AHL) mediated Quorum Sensing (QS): 5. 
Inhibitors of AHL synthase LuxI. 6. AHL degrading enzymes (e.g. lactonase and 
acylase). 7. Inhibitors of AHL binding to transcriptional regulator LuxR.   
 
Figure 3. Schematic representation of the DSB catalytic cycle. Quinones (labeled 
Q) generate disulfides in DsbB (orange), which are transferred to DsbA (green), 
which catalyses oxidative protein folding in substrate virulence factors (blue; and 
indicated above). In concert, the disulfide in DsbA (labeled S-S) is reduced to two 
thiols (labeled SH) to complete the catalytic cycle. 
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